November 18, 2026
Health news, explained with evidence
LIVE
Understanding and Addressing Love Handles Through Lifestyle Changes Ciele Releases New Woolmark-Certified Merino Winter Running Apparel Preventive Services Task Force Resumes Meetings Under New Leadership Blood-Based Genetic Signature May Predict CAR T-Cell Therapy Success in Lymphoma Ultraprocessed Diets May Impact Brain Reward Systems in Younger Adults Addressing Body Image and the Reality of Gluteal Anatomy Migraine and Smoking Linked to Increased Early Stroke Risk in Women CBD Oil Found Ineffective for Managing Behavioral Issues in Youths with Intellectual Disabilities Expert Advice on Hydration Gear Sparks Debate Among Recreational Runners A Structured Approach to Beginning a Strength and Cardio Routine Understanding and Addressing Love Handles Through Lifestyle Changes Ciele Releases New Woolmark-Certified Merino Winter Running Apparel Preventive Services Task Force Resumes Meetings Under New Leadership Blood-Based Genetic Signature May Predict CAR T-Cell Therapy Success in Lymphoma Ultraprocessed Diets May Impact Brain Reward Systems in Younger Adults Addressing Body Image and the Reality of Gluteal Anatomy Migraine and Smoking Linked to Increased Early Stroke Risk in Women CBD Oil Found Ineffective for Managing Behavioral Issues in Youths with Intellectual Disabilities Expert Advice on Hydration Gear Sparks Debate Among Recreational Runners A Structured Approach to Beginning a Strength and Cardio Routine

Shorter Dosing Schedule Maintains Efficacy in Refractory Colorectal Cancer Treatment, Trial Finds

❤️ Conditions & Care 2 min read 👁 5

A phase III clinical trial from Japan shows that a condensed 14-day cycle for refractory metastatic colorectal cancer treatment is as effective as the traditional 28-day schedule while lowering adverse side effects.

Shorter Dosing Schedule Maintains Efficacy in Refractory Colorectal Cancer Treatment, Trial Finds❤️Conditions & Care

Photo: medpagetoday.com

Key points

  • The phase III PRABITAS trial evaluated 972 patients comparing a 14-day cycle against a standard 28-day cycle of FTD-TPI plus bevacizumab.
  • Median overall survival was 10.3 months for the 28-day group and 11.3 months for the 14-day group, meeting noninferiority criteria.
  • The shorter schedule significantly reduced the incidence of severe neutropenia and anorexia.

A shorter dosing schedule for a standard therapy combination used in treating refractory metastatic colorectal cancer preserves overall survival while reducing adverse side effects, according to findings from the phase III PRABITAS trial led by researchers in Japan and published in The Lancet.

The study evaluated 972 patients across 178 hospitals comparing the conventional 28-day regimen of trifluridine-tipiracil (FTD-TPI) combined with bevacizumab against a condensed 14-day schedule. Researchers observed a median overall survival of 10.3 months in the conventional group compared with 11.3 months in the shorter-schedule group, successfully meeting the study's threshold for noninferiority. Secondary measures, such as progression-free survival, were similar across both arms at 3.9 months.

Crucially, the 14-day schedule was linked to a lower burden of toxicities. Grade 3 or higher neutropenia dropped from 39% in the 28-day group to 13% in the shorter-course group, and occurrences of grade 2 or higher anorexia also declined. Accompanying editorialists noted that while the trial successfully demonstrated reduced toxicity and simplified administration, it did not formally assess whether these adjustments translated into measurable improvements in overall quality of life.

What to know: A condensed 14-day cycle for FTD-TPI plus bevacizumab appears noninferior in survival outcomes to the standard 28-day regimen while significantly decreasing certain hematologic and non-hematologic toxicities. Patients should consult their healthcare providers to discuss individualized treatment plans and the most appropriate care strategies.

Source medpagetoday.com — medpagetoday.com/hematologyoncology/coloncancer/123883 ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.